Eosinophilic myopathic syndromes

Current Opinion in Rheumatology

Volumn 10, Issue 6, 1998, Pages 504-510

  Pickering, Matthew Caleb ^a   Walport, Mark Jeremy ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; STEROID; TRANILAST; TRYPTOPHAN;

DERMATOMYOSITIS; EOSINOPHILIA; EOSINOPHILIA MYALGIA SYNDROME; EOSINOPHILIC FASCIITIS; EOSINOPHILIC MYOPATHY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; MYOPATHY; PARASITOSIS; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; TOXIC OIL SYNDROME;

EOSINOPHILIA; EOSINOPHILIA-MYALGIA SYNDROME; EOSINOPHILS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MUSCULAR DISEASES; SYNDROME;

EID: 0031768696     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199811000-00002     Document Type: Review

References (89)

1. Hall FC, Krausz T, Walport MJ: Idiopathic eosinophilic myositis. Q J Med 1995, 88:581-586.
2. Kaufman LD, Kephart GM, Seidman RJ, Buhner D, Qvarfordt I, Nassberger L, Gleich GJ: The spectrum of eosinophilic myositis: clinical and immunopathogenic studies of three patients, and review of the literature. Arthritis Rheum 1993, 36:1014-1024.
3. Agrawal BL, Giesen PC: Eosinophilic myositis: an unusual cause of pseudotumor and eosinophilia. JAMA 1981, 246:70-71.
4. Sladek GD, Vasey FB, Sieger B, Behnke DA, Germain BF, Espinoza LR: Relapsing eosinophilic myositis. J Rheumatol 1983, 10:467-470.
5. Yonker RA, Panush RS: Idiopathic eosinophilic myositis with preexisting fibromyalgia. J Rheumatol 1985, 12:165-167.
6. Kamm MA, Dennett X, Byrne E: Relapsing eosinophilic myositis: a cause of pseudothrombophlebitis in an alcoholic. J Rheumatol 1987, 14:831-34.
7. Espino-Montoro A, Medina M, Marin-Martin J, Jimenez Gonzalo FJ, Moalla AK, Fernandez-Gonzalez G, Vahi R: Idiopathic eosinophilic myositis associated with vasculitis and symmetrical polyneuropathy. Br J Rheumatol 1997, 36:276-279. First report of eosinophilic myositis associated with vasculitis and symmetrical polyneuropathy.
8. Strosberg JM, Lava NS: Polymyositis with eosinophilic and mononeuropathy multiplex [letter]. J Rheumatol 1981, 8:523-526.
9. Layzer RB, Shearn MA, Satya-Murti S: Eosinophilic polymyositis. Ann Neurol 1977, 1:65-71.
10. Stark RJ: Eosinophilic polymyositis. Arch Neurol 1979, 36:721-722.
11. Trueb RM, Pericin M, Winzeler B, Wuthrich B, Burg G: Eosinophilic myositis/perimyositis: frequency and spectrum of cutaneous manifestations. J Am Acad Dermatol 1997, 37:385-391. A description of cutaneous lesions in idiopathic eosinophilic myopathy and a review of the literature.
12. Serratrice G, Pellissier JF, Cros D, Gastaut JL, Brindisi G: Relapsing eosinophilic perimyositis. J Rheumatol 1980, 7:199-205.
13. Fang MA, Verity MA, Paulus HE: Subacute perimyositis. J Rheumatol 1988, 15:1291-1293.
14. Trueb RM, Becker-Wegerich P, Hafner J, Wuthrich B, Burg G: Relapsing eosinophilic perimyositis. Brit J Dermatol 1995, 133:109-114.
15. Lakhanpal S, Duffy J, Engel AG: Eosinophilia associated with perimyositis and pneumonitis. Mayo Clin Proc 1988, 63:37-41.
16. Symmans WA, Beresford CH, Bruton D, Despommier DD, Dickson D, Linehan BJ, et al.: Cyclic eosinophilic myositis and hyperimmunoglobulin-E. Ann Intern Med 1986, 104:26-32.
17. Hardy WR, Anderson RE: The hypereosinophilic syndrome. Ann Intern Med 1968, 68:1220.
18. Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 1975, 54:1-27.
19. Weller PF, Bubley GJ: The idiopathic hypereosinophilic syndrome. Blood 1994, 83:2759-2779.
20. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH: NIH conference. The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982, 97:78-92.
21. Lefebvre C, Bletry O, Degoulet P, Guillevin L, Bentata-Pessayre M, Le Thi Huong D, Godeau P: Prognostic factors of hypereosinophilic syndrome: study of 40 cases. Ann Med Interne 1989, 140:253-257.
22. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF: Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983, 52:1-22.
23. Pye M, Pope R, Jones JH, Williams G: Eosinophilic polymyositis presenting as a pseudotumour in the hypereosinophilic syndrome. Br J Rheumatol 1987, 26:384-385.
24. Lee JD, Chen ST, Chen CJ, Chen CM, Ro LS: Idiopathic hypereosinophilic syndrome with eosinophilic myositis, peripheral neuropathy and central nervous system involvement. J Formosan Med Assoc 1996, 95:933-936.
25. Sato A, Kobayashi K, Okabe H, Fukuda S: A case of the hypereosinophilic syndrome complicated by malignant lymphoma. J Dermatol 1983, 10:75-80.
26. Kim CJ, Park SJ, Chi JG: Idiopathic hypereosinophilic syndrome terminating as disseminated T cell lymphoma. Cancer 1991, 67:1064-1069.
27. Brugnoni D, Airo P, Rossi G, Bettinardi A, Simon HU, Garza L, et al.: A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 1996, 87:1416-1422.
28. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M: Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994, 330:535-538.
29. Arase S, Kato S, Nakanishi H, Sadamoto Y, Urano Y, Kawai H, Takeda K: Eosinophilic polymyositis induced by tranilast. J Dermatol 1990, 17:182-186.
30. Fenoglio JJ Jr, McAllister HA Jr, Mullick FG: Drug related myocarditis: I. Hypersensitivity myocarditis. Hum Pathol 1981, 12:900-907.
31. Bocanegra TS, Vasey FB: Musculoskeletal syndromes in parasitic diseases. Rheum Dis Clin North Am 1993, 19:505-513.
32. Ely RW, Fox JC: Elevated IgG antibody to Sarcocystis cruzi associated with eosinophilic myositis in cattle. J Vet Diagn Invest 1989, 1:53-56.
33. Jensen R, Alexander AF, Dahlgren RR, Jolley WR, Marquardt WC, Flack DE, et al.: Eosinophilic myositis and muscular sarcocystosis in the carcasses of slaughtered cattle and lambs. Am J Vet Res 1986, 47:587-593.
34. Gajadhar AA, Marquardt WC: Ultrastructural and transmission evidence of Sarcocystis cruzi associated with eosinophilic myositis in cattle. Can J Vet Res 1992, 56:41-46.
35. Smith HJ, Snowdon KE, Finley GG: Eosinophilic myositis in Canadian cattle. Can J Vet Res 1991, 55:94-95.
36. Terrell TG, Stookey JL: Chronic eosinophilic myositis in a rhesus monkey infected with sarcosporidiosis. Vet Pathol 1972, 9:266-271.
37. Van den Enden E, Praet M, Joos R, Van Gompel A, Gigasse P: Eosinophilic myositis resulting from sarcocystosis. J Trop Med Hyg 1995, 98:273-276.
38. Aufdemorte TB, Huntington HW, Ripley JF, Ramzy I: Localized eosinophilic myositis of the masseter muscle associated with actinomycosis. J Oral Maxillofac Surg 1983, 41:196-200.
39. Kilbourne EM, Rigau-Perez JG, Heath CW Jr, Zack MM, Falk H, Martin-Marcos M, de Carlos A: Clinical epidemiology of toxic-oil syndrome: manifestations of a new illness. N Engl J Med 1983, 309:1408-1414.
40. Anonymous: Toxic epidemic syndrome, Spain, 1981, Toxic Epidemic Syndrome Study Group. Lancet 1982, 2:697-702.
41. Martinez-Tello FJ, Navas-Palacios JJ, Ricoy JR, Gil-Martin R, Conde-Zurita JM, Colina-Ruiz Delgado F, et al.: Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain. Virch Arch 1982, 397:261-285.
42. Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ: Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990, 322:869-873.
43. Eidson M, Philen RM, Sewell CM, Voorhees R, Kilbourne EM: L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990, 335:645-648.
44. Anonymous: Eosinophilia-myalgia syndrome and L-tryptophan-containing products: New Mexico, Minnesota, Oregon, and New York, 1989. MMWR Morbid Mortal Wkly Rep 1989, 38:785-788.
45. Hertzman PA, Clauw DJ, Kaufman LD, Varga J, Silver RM, Thacker HL, et al.: The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset. Ann Intern Med 1995, 122:851-855.
46. Silver RM: Pathophysiology of the eosinophilia-myalgia syndrome. J Rheumatol Suppl 1996, 46:26-36.
47. Emslie-Smith AM, Engel AG, Duffy J, Bowles CA: Eosinophilia myalgia syndrome: I. Immunocytochemical evidence for a T-cell-mediated immune effector response. Ann Neurol 1991, 29:524-528.
48. Hollander D, Adelman LS: Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan: muscle biopsy findings in 4 patients. Neurology 1991, 41:319-321.
49. Turi GK, Solitare GB, James N, Dicker R: Eosinophilia-myalgia syndrome (L-tryptophan-associated neuromyopathy). Neurology 1990, 40:1793-1796.
50. Varga J, Griffin R, Newman JH, Jimenez SA: Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. J Rheumatol 1991, 18:259-263.
51. Shulman LE: Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975, 88:70-86.
52. Rodnan GP, DiBartolomeo A, Medsger TA: Proceedings: eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome [abstract]. Arthritis Rheum 1975, 18:525.
53. Moore TL, Zuckner J: Eosinophilic fasciitis. Semin Arthritis Rheum 1980, 9:228-235.
54. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB: Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988, 17:221-231.
55. Barnes L, Rodnan GP, Medsger TA, Short D: Eosinophilic fasciitis: a pathologic study of twenty cases. Am J Pathol 1979, 96:493-517.
56. Schumacher HR: A scleroderma-like syndrome with fasciitis, myositis, and eosinophilia [letter]. Ann Intern Med 1976, 84:49-50.
57. King DF, Dore RK, Gilbert DJ, Gurevitch AW, Hirose FM: Generalized morphea with peripheral eosinophilia, fasciitis and myositis. Int J Dermatol 1980, 19:149-153.
58. Kaplinsky N, Revach M, Katz WA: Eosinophilic fasciitis: report of a case with features of connective tissue diseases. J Rheumatol 1980, 7:536-540.
59. Bjelle A, Henriksson KG, Hofer PA: Polymyositis in eosinophilic fasciitis: review and case report. Eur Neurol 1980, 19:128-137.
60. Hibbs JR, Mittleman B, Hill P, Medsger TA: L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak. Arthritis Rheum 1992, 35:299-303.
61. Onodera J, Hayashi T, Chida K, Shiga Y, Mochizuki H, Itoyama Y: A case of Ki-1 lymphoma-associated eosinophilic polymyositis. Rinsho Shinkeigaku 1997, 37:314-318.
62. Kuo TT, Shih LY, Chan HL: Kimura's disease: involvement of regional lymph nodes and distinction from angiolymphoid hyperplasia with eosinophilia. Am J Surg Path 1988, 12:843-854.
63. Lanham JG, Elkon KB, Pusey CD, Hughes GR: Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984, 63:65-81.
64. Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood 1992, 79:3101-3109.
65. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, et al.: IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996, 4:15-24.
66. Dent LA, Strath M, Mellor AL, Sanderson CJ: Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990, 172:1425-1431.
67. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T: Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991, 78:2542-2547.
68. Egan RW, Athwahl D, Chou CC, Emtage S, Jehn CH, Kung TT, et al.: Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int Arch Allergy Immunol 1995, 107:321-322.
69. Trueb RM, Lubbe J, Torricelli R, Panizzon RG, Wuthrich B, Burg G: Eosinophilic myositis with eosinophilic cellulitislike skin lesions: association with increased serum levels of eosinophil cationic protein and interleukin-5. Arch Dermatol 1997, 133:203-206.
70. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A: Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989, 19:701-705.
71. Fredrikson LJ, Lee JJ, Lee NA: Skin-specific expression of interleukin-5 in transgenic mice: characterization of the resulting leukocyte infiltrate and pathophysiological responses [abstract]. J Invest Dermatol 1996, 106:937.
72. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, et al.: Eotaxin: a potent eosinophil chemoattractant cytokine in a guinea pig model of airways inflammation. J Exp Med 1994, 179:881-887.
73. Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P: Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997, 185:785-790.
74. Kitaura M, Nakajima T, Imai T, Harada S, Combadiere C, Tiffany HL, et al.: Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 1996, 271:7725-7730.
75. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, et al.: Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996, 183:2437-2448.
76. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS: Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996, 183:2349-2354.
77. Sallusto F, Mackay CR, Lanzavecchia A: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997, 277:2005-2007. The presence of the eotaxin receptor on T helper cells promotes allergen-driven production of interleukin-5 and eosinophil activation.
78. Rothenberg ME, Ownbey R, Mehlhop PD, Loiselle PM, van de Rijn M, Bonventre JV, et al.: Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Medicine 1996, 2:334-348.
79. Mould AW, Matthaei KJ, Young IG, Foster PS: Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 1997, 99:1064-1071.
80. Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O, et al.: Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997, 159:4593-4601.
81. Teixeira MM, Wells TN, Lukacs NW, Proudfoot AE, Kunkel SL, Williams TJ, Hellewell PG: Chemokine-induced eosinophil recruitment: evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest 1997, 100:1657-1666.
82. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, et al.: Chemokine receptor usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997, 99:178-184.
83. Anderson DC, Schmalsteig FC, Finegold MJ, Hughes BJ, Rothlein R, Miller LJ, et al.: The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis 1985, 152:668-689.
84. Walsh GM, Mermod JJ, Hartnell A, Kay AB, Wardlaw AJ: Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol 1991, 146:3419-3423.
85. Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K, Sanderson CJ, Kay AB: IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology 1990, 71:258-265.
86. Weller PF: The immunobiology of eosinophils. N Eng J Med 1991, 324:1110-1118.
87. Fujisawa T, Abu-Ghazaleh R, Kita H, Sanderson CJ, Gleich GJ: Regulatory effect of cytokines on eosinophil degranulation. J Immunol 1990, 144:642-646.
88. Yukawa T, Kroegel C, Evans P, Fukuda T, Chung KF, Barnes PJ: Density heterogeneity of eosinophil leucocytes: induction of hypodense eosinophils by platelet-activating factor. Immunology 1989, 68:140-143.
89. Tenscher K, Metzner B, Schopf E, Norgauer J, Czech W: Recombinant human eotaxin induces oxygen radical production, Ca(2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. Blood 1996, 88:3195-3199.